Pharmaceutical Technology on MSN
Aktis Oncology kicks 2026 IPO cycle off with $210m target
"Aktis Oncology kicks 2026 IPO cycle off with $210m target" was originally created and published by Pharmaceutical Technology ...
The recent IPO boom signals confidence in India’s economic story, but confidence should not slide into complacency ...
Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest.
Opinion
10hOpinion
BCCL IPO: Cheap on paper, costly in a downcycle; why Coal India may be the smarter pick
BCCL's IPO may appear cheap, but Coal India offers more stable, diversified returns, making it the smarter investment choice.
A potential initial public offering (IPO) next year by cryptocurrency exchange Kraken may attract fresh capital from traditional finance (TradFi) investors. Bitcoin recorded an all-time high price ...
Kotak’s Sanjeev Prasad says only ’15-20% Of IPO funds used for asset creation’ — 5 key 2026 insights
IPO funds used mainly for promoter exits, not assets—see Sanjeev Prasad’s 2026 outlook and market drivers. Read key insights ...
An IPO-focused ETF adds Medline early, signaling renewed Wall Street enthusiasm as IPO activity begins to heat up again.
Dalal Street is preparing for what could be its biggest year in the primary market, with 2026 expected to be a record-breaker ...
London had its strongest year for IPOs in 2025 since 2021, according to PwC ’s latest IPO Watch EMEA 2025.
Bharat Coking Coal's initial public offering begins Friday, marking the year's first major public sale. Strong market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback